• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

LivaNova

MedTech 100 roundup: Industry sees largest fall since October

March 8, 2021 By Sean Whooley

The medtech industry’s hot start to 2021 has finally come to a full halt after stocks fell harder than they had in more than four months. MassDevice‘s MedTech 100 index ended the week (March 5) at 103.3 points, marking a -3.1% dip from the 106.65-point mark set one week before (Feb. 26). In less than a […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Mergers & Acquisitions, Wall Street Beat Tagged With: Amgen, Asensus Surgical, BD, becton dickinson, Boston Scientific, Colfax Corp., conformis, coronavirus, COVID-19, Five Prime Therapeutics, GSL Solutions, Hillrom, LivaNova, MedTech 100 Index, Medtronic, Permira, Senseonics, TransEnterix

Report: Permira eyeing LivaNova purchase

March 4, 2021 By Sean Whooley

Private equity firm Permira has reportedly submitted a bid to acquire LivaNova (NSDQ:LIVN), which is valued at $3.7 billion. The Financial Times reported that people familiar with the situation cited an offer made in mid-February that valued London-based LivaNova’s shares at more than $80 per share. The report said talks are ongoing but there is no […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: LivaNova, Permira

LivaNova slides despite Street-beating Q4

February 24, 2021 By Sean Whooley

LivaNova (NSDQ:LIVN) shares took a dip this morning despite fourth-quarter results that topped the consensus forecast. The London-based company posted losses of $279.8 million, or -$5.75 per share, on sales of $269.6 million for the three months ended Dec. 31, 2020, for a 95.4% bottom-line slide deeper into the red on a sales decline of -6.3%. […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, Replacement Heart Valves, Structural Heart, Wall Street Beat Tagged With: LivaNova

LivaNova selling off heart valve business to Gyrus Capital

December 3, 2020 By Sean Whooley

LivaNova (NSDQ:LIVN) announced today that it has agreed to sell its heart valve business to Gyrus Capital. London-based LivaNova’s board of directors unanimously approved the divestiture of the heart valve business in an effort to enable the company to “sharpen its focus” within its primary platforms, such as neuromodulation and cardiovascular, according to a news release. […]

Filed Under: Business/Financial News, Cardiac Implants, Cardiovascular, Featured, Mergers & Acquisitions, Replacement Heart Valves, Structural Heart Tagged With: Gyrus Capital, LivaNova

Study: ECMO ‘significantly’ improves heart attack patients’ survival

November 13, 2020 By Sean Whooley

The National Institutes of Health (NIH) is touting a study that found the use of life support improved survival in certain cardiac arrest patients. Published in The Lancet, the study, known as the Advanced Reperfusion Strategies for Refractory Cardiac Arrest (ARREST) trial, used the life support machine called extracorporeal membrane oxygenation ECMO to replicate the […]

Filed Under: Cardiovascular, Clinical Trials, Featured Tagged With: Abiomed, and Blood Institute NHLBI, coronavirus, COVID-19, LivaNova, Medtronic, National Institutes of Health (NIH)

LivaNova stock up on Street-beating Q3, CFO departing

October 29, 2020 By Chris Newmarker

LivaNova (NSDQ:LIVN) posted third-quarter results today that beat the consensus forecast on Wall Street, though the company still expects full-year sales between –7% and –17% on a constant-currency basis. LivaNova also announced that CFO Thad Huston will leave his position by Oct. 31 — after serving three and a half years with the company. Alex Shvartsburg, […]

Filed Under: Business/Financial News, Cardiovascular, Featured, Wall Street Beat Tagged With: LivaNova, Personnel Moves

LivaNova slides despite forecast-topping Q2 results

July 29, 2020 By Sean Whooley

LivaNova (NSDQ:LIVN) shares dipped today despite second-quarter results that beat the consensus forecast. The London-based medtech company posted losses of -$88 million, or -$1.81 per share, on sales of $182.2 million for the three months ended June 30, 2020, for a massive bottom-line slide from losses of $29.2 million this time last year on a sales […]

Filed Under: Business/Financial News, Cardiovascular, MassDevice Earnings Roundup, Neuromodulation/Neurostimulation, Wall Street Beat Tagged With: coronavirus, COVID-19, LivaNova

LivaNova touts results of sutureless aortic valve study

May 28, 2020 By Sean Whooley

LivaNova (NSDQ:LIVN) said today that its Perceval sutureless implant is safe and effective compared to standard aortic valve replacement, according to a clinical study. The study, presented at the 100th annual meeting of the American Association of Thoracic Surgery (AATS), revealed that the Perceval sutureless surgical aortic valve demonstrated freedom from major adverse cerebral and cardiovascular […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Featured, Replacement Heart Valves, Structural Heart Tagged With: LivaNova

LivaNova touts results of VNS treatment for bipolar depression

May 20, 2020 By Nancy Crotti

LivaNova (NSDQ:LIVN) today announced the publication of a new study that showed adding vagus nerve stimulation (VNS) therapy to treatment-as-usual significantly improves outcomes in patients with treatment-resistant bipolar depression (TRBD). Published in the International Journal of Bipolar Disorders, the study examined patients from a 5-year prospective registry and found 63% of 97 patients treated with VNS plus […]

Filed Under: Clinical Trials, Featured, Neuromodulation/Neurostimulation Tagged With: LivaNova, VNS

LivaNova cardiopulmonary devices can be used longer under FDA coronavirus guidance

April 22, 2020 By Sean Whooley

LivaNova (NSDQ:LIVN) announced that some of its cardiopulmonary products are now permitted for extended use in specific therapies after the FDA expanded device availability amid the COVID-19 pandemic. On April 6, the FDA issued guidance to temporarily expand the availability of certain devices in an effort to address the coronavirus crisis. Along the guidelines given by […]

Filed Under: Blood Management, Cardiovascular, Food & Drug Administration (FDA), Regulatory/Compliance, Vascular Tagged With: coronavirus, COVID-19, FDA, LivaNova

LivaNova lands CE Mark for depression neurostimulation treatment

March 9, 2020 By Nancy Crotti

LivaNova (NSDQ:LIVN) said today that its vagus nerve stimulation therapy for treatment-resistant depression has won the CE Mark in Europe. Two patients in the United Kingdom were implanted with the company’s Symmetry system at the Musgrove Park Hospital in Taunton, England, making them the first patients to receive Symmetry devices outside the United States. The ability […]

Filed Under: Business/Financial News, Featured, Neuromodulation/Neurostimulation, Regulatory/Compliance, Wall Street Beat Tagged With: CE Mark, LivaNova, Medtronic

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 11
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy